Parametric Portfolio Associates LLC Has $473,000 Stake in Neuroderm Ltd (NDRM)
Parametric Portfolio Associates LLC held its position in shares of Neuroderm Ltd (NASDAQ:NDRM) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,816 shares of the biotechnology company’s stock at the end of the 2nd quarter. Parametric Portfolio Associates LLC owned 0.06% of Neuroderm worth $473,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Menora Mivtachim Holdings LTD. raised its position in Neuroderm by 18.6% in the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 808,073 shares of the biotechnology company’s stock valued at $24,161,000 after purchasing an additional 126,517 shares during the last quarter. Wells Fargo & Company MN raised its position in Neuroderm by 55,181.2% in the 2nd quarter. Wells Fargo & Company MN now owns 373,148 shares of the biotechnology company’s stock valued at $11,157,000 after purchasing an additional 372,473 shares during the last quarter. FMR LLC raised its position in Neuroderm by 30.0% in the 2nd quarter. FMR LLC now owns 260,039 shares of the biotechnology company’s stock valued at $7,775,000 after purchasing an additional 60,039 shares during the last quarter. C WorldWide Group Holding A S purchased a new stake in Neuroderm in the 2nd quarter valued at $2,775,000. Finally, Sphera Funds Management LTD. purchased a new stake in Neuroderm in the 2nd quarter valued at $2,228,000. Hedge funds and other institutional investors own 52.39% of the company’s stock.
Several analysts recently commented on NDRM shares. Jefferies Group LLC reiterated a “buy” rating and issued a $42.00 price target on shares of Neuroderm in a research report on Monday, August 14th. Zacks Investment Research upgraded shares of Neuroderm from a “sell” rating to a “hold” rating in a research report on Wednesday, October 18th. Finally, Roth Capital downgraded shares of Neuroderm from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $33.00 to $39.00 in a research report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Neuroderm has an average rating of “Buy” and an average target price of $45.86.
Neuroderm Ltd (NASDAQ:NDRM) opened at $38.85 on Friday. Neuroderm Ltd has a 12-month low of $15.20 and a 12-month high of $38.95.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Want to see what other hedge funds are holding NDRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neuroderm Ltd (NASDAQ:NDRM).
Receive News & Ratings for Neuroderm Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuroderm Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.